Solid Biosciences financials
$7.16−1.65%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $8.1M | $13.6M | — | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $8.1M | $13.6M | — | $0.00 | $0.00 |
| Gross margin | — | — | — | 100.0% | 100.0% | — | — | — |
| Operating income | -$179.2M | -$129.7M | -$104.3M | -$106.5M | -$72.3M | -$88.4M | -$119.3M | -$75.7M |
| Net income | -$174.3M | -$124.7M | -$96.0M | -$86.0M | -$72.2M | -$88.3M | -$117.2M | -$74.8M |
| Net margin | — | — | — | −1062.3% | −530.0% | — | — | — |
| Diluted EPS | $-1.99 | $-3.06 | $-4.83 | $-10.10 | $-10.14 | $-25.50 | $-43.65 | $-33.75 |
| EBITDA | -$177.6M | -$127.3M | -$101.7M | -$96.9M | -$69.3M | -$82.5M | -$116.5M | -$74.1M |
| Operating cash flow | -$156.3M | -$100.0M | -$94.2M | -$98.0M | -$77.8M | -$56.6M | -$92.7M | -$70.2M |
| Free cash flow | -$157.4M | -$100.7M | -$95.7M | -$101.0M | -$79.0M | -$57.5M | -$97.1M | -$78.0M |
| Diluted shares | 87.5M | 40.8M | 19.9M | 8.5M | 7.1M | 3.5M | 2.7M | 2.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $59.9M | $80.2M | $74.0M | $155.4M | $119.1M | $154.7M |
| Short-term investments | $128.0M | $68.7M | $49.6M | $58.3M | $88.6M | — |
| Total debt | $0.00 | $1.2M | $1.7M | $2.4M | $525.0K | $733.0K |
| Total assets | $232.5M | $188.7M | $164.9M | $260.3M | $232.4M | $171.2M |
| Total liabilities | $52.5M | $51.4M | $38.5M | $48.6M | $24.2M | $39.1M |
| Shareholders' equity | $180.0M | $137.2M | $126.5M | $211.7M | $208.2M | $132.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology